Celanese Corporation
CE
$53.50
+0.02%
Celanese Corporation is a global chemical and specialty materials company, operating primarily in the Basic Materials sector. It is one of the world's largest producers of acetic acid and its derivatives, and a leading producer of specialty polymers used in automotive, electronics, medical, and consumer end markets, with a notable position in cellulose derivatives for cigarette filters. The current investor narrative is dominated by the company's volatile earnings recovery and significant debt load, as recent quarterly results show a stark turnaround from a massive net loss in Q3 2025 to a return to profitability in Q4 2025, sparking debate over the sustainability of its margin improvement and cash flow generation amidst a challenging chemical industry environment.…
CE
Celanese Corporation
$53.50
Investment Opinion: Should I buy CE Today?
Rating: Hold. The core thesis is that Celanese presents a high-risk, high-potential-reward situation where compelling valuation and cash flow are counterbalanced by severe leverage and earnings volatility, warranting a neutral stance pending clearer signs of a sustained turnaround.
Supporting evidence includes a forward P/E of only 8.6x based on analyst EPS of $11.95, a deep discount to sales (PS of 0.49 vs. industry >1.0), and strong trailing free cash flow of $803 million. However, these positives are offset by a debt-to-equity ratio of 3.19, a negative trailing net margin of -12.2%, and a recent 12.25% monthly price decline indicating severe market skepticism.
The thesis would upgrade to a Buy if the company demonstrates consecutive quarters of positive net income while reducing leverage, or if the stock price falls near the $35 support level, offering a larger margin of safety. It would downgrade to a Sell if Q4 profitability proves an anomaly and net losses return, or if free cash flow turns negative, jeopardizing debt service. Relative to its history and challenged peers, the stock is fairly valued to slightly undervalued, but the discount is justified by its elevated risk profile.
Sign up to view all
CE 12-Month Price Forecast
The outlook for Celanese is bifurcated between its attractive valuation/cash flow profile and its dangerous leverage/volatility. The base case of range-bound trading is most likely, as the market awaits proof that the Q4 recovery is sustainable. The stance would upgrade to bullish on evidence of sequential debt reduction and consistent profitability across two more quarters. It would turn bearish if the next quarterly report shows a return to negative net income or a contraction in free cash flow. The wide analyst EPS range underscores the high uncertainty embedded in this name.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Celanese Corporation's 12-month outlook, with a consensus price target around $69.55 and implied upside of +30.0% versus the current price.
Average Target
$69.55
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$43 - $70
Analyst target range
Analyst coverage for Celanese is limited, with only 5 analysts providing estimates, indicating it may be under-followed by the broader institutional research community which can contribute to higher volatility. The consensus earnings estimate for the upcoming period is $11.95 per share, with a wide range from a low of $11.08 to a high of $13.31, reflecting substantial uncertainty in forward projections. The wide dispersion between the low and high EPS targets, a spread of nearly 20%, signals low conviction and high variability in modeling assumptions, likely tied to the volatile nature of chemical input costs, end-market demand, and the company's ability to sustain its recent return to profitability.
Bulls vs Bears: CE Investment Factors
The evidence is finely balanced but tilts slightly bearish in the near term due to the unresolved high leverage and recent severe loss of momentum. The bull case rests on a deep valuation discount and a cash-generative business showing signs of a sharp earnings recovery. The bear case emphasizes unsustainable financial risk and volatile fundamentals. The single most important tension in the investment debate is whether the Q4 profitability rebound marks the beginning of a sustainable recovery that can steadily de-lever the balance sheet, or is merely a temporary respite before another cyclical downturn in the challenging chemical industry. The resolution of this tension will dictate whether the current valuation represents a deep-value opportunity or a value trap.
Bullish
- Deep Valuation Discount: Celanese trades at a trailing PS ratio of 0.49 and a forward PS of 0.52, a significant discount to the chemical industry average often above 1.0. This valuation is near the bottom of its multi-year historical range, suggesting the market has priced in severe pessimism, creating a potential margin of safety for value investors.
- Strong Free Cash Flow Generation: The company generated $803 million in trailing free cash flow, providing substantial liquidity. This robust cash flow, coupled with a healthy current ratio of 1.55, offers a buffer to service its high debt load and fund operations without external financing.
- Dramatic Profitability Recovery: Q4 2025 showed a sharp turnaround to a net income of $19 million from a catastrophic $1.357 billion loss in Q3. This sequential improvement, driven by the Engineered Materials segment, indicates the company's operations are stabilizing and can generate positive earnings.
- Analyst EPS Forecast Implies Value: The consensus forward EPS estimate of $11.95 implies a forward P/E of just 8.6. This low multiple, based on a return to substantial profitability, suggests the stock is undervalued if the company can meet or exceed these earnings expectations.
Bearish
- Extremely High Financial Leverage: A debt-to-equity ratio of 3.19 signifies a highly leveraged balance sheet. This elevates financial risk, making the company vulnerable to interest rate hikes and economic downturns, and constrains strategic flexibility.
- Volatile and Negative Profitability: Trailing twelve-month metrics show a net margin of -12.2% and an ROE of -28.8%, reflecting deep losses over the past year. While Q4 was positive, the extreme volatility from a $1.36B loss to a $19M profit raises questions about earnings sustainability.
- Revenue Decline and Weak Growth: Q4 2025 revenue of $2.204B declined 7% year-over-year. The lack of top-line growth, amidst a recovery in profitability, suggests the turnaround is driven by cost-cutting rather than organic demand, which may have limits.
- Low Analyst Coverage and High Uncertainty: Only 5 analysts cover the stock, indicating it is under-followed and prone to higher volatility. The wide EPS estimate range from $11.08 to $13.31 (a 20% spread) reflects low conviction and high modeling uncertainty regarding future performance.
CE Technical Analysis
The stock is in a pronounced downtrend over the very short term, having declined 12.25% over the past month, which contrasts sharply with its strong 45.87% gain over the last six months. The current price of $56.80 positions the stock at approximately 45% of its 52-week range ($35.13 to $70.70), indicating it is much closer to its yearly low than its high, which suggests the recent sell-off has moved it into a zone of potential oversold conditions or heightened fundamental concern. The 3-month price change of -3.48% further confirms the recent loss of momentum, diverging negatively from the longer-term 6-month uptrend and signaling a potential trend reversal or significant consolidation phase. The stock's beta of 0.808 indicates it has been less volatile than the broader market, yet its recent 1-month underperformance versus the S&P 500 (which gained 5.6%) by -17.85 percentage points highlights severe company-specific or sector-specific headwinds. Key technical support is clearly defined at the 52-week low of $35.13, while resistance sits at the recent high of $70.70; a sustained break below the recent low near $56 could signal a test of lower support levels, whereas reclaiming the $65-$70 zone would be necessary to re-establish bullish momentum.
Beta
0.81
0.81x market volatility
Max Drawdown
-43.0%
Largest decline past year
52-Week Range
$35-$71
Price range past year
Annual Return
-0.4%
Cumulative gain past year
| Period | CE Return | S&P 500 |
|---|---|---|
| 1m | -15.8% | +4.6% |
| 3m | -2.6% | +8.3% |
| 6m | +41.0% | +12.5% |
| 1y | -0.4% | +25.0% |
| ytd | +26.9% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CE Fundamental Analysis
Revenue growth has been inconsistent and recently negative, with Q4 2025 revenue of $2.204 billion representing a 7% year-over-year decline, although this followed a disastrous Q3 where revenue was $2.419 billion and the company posted a net loss of $1.357 billion. The sequential improvement from Q3 to Q4, driven by a rebound in the Engineered Materials segment ($1.277 billion in Q4) versus Acetyl Chain ($940 million), suggests stabilization but not a robust growth trajectory. Profitability remains a critical concern, as evidenced by a trailing twelve-month net margin of -12.2% and a gross margin of 18.8%, though the most recent quarterly data shows a significant recovery with Q4 net income of $19 million and a gross margin of 17.4%, indicating the company is clawing back from deep losses. The balance sheet carries substantial leverage with a debt-to-equity ratio of 3.19, which elevates financial risk, but this is partially offset by a healthy current ratio of 1.55 and strong trailing free cash flow of $803 million, providing some liquidity to service debt and fund operations internally.
Quarterly Revenue
$2.2B
2025-12
Revenue YoY Growth
-0.07%
YoY Comparison
Gross Margin
+0.17%
Latest Quarter
Free Cash Flow
$803000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CE Overvalued?
Given the company's negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. Celanese trades at a trailing PS ratio of 0.49 and a forward PS ratio implied by analyst revenue estimates of approximately 0.52, indicating a very modest expectation for sales growth. This valuation represents a significant discount to the broader chemical industry, which often trades at PS ratios above 1.0, reflecting the market's skepticism about profitability and growth prospects. Historically, the stock's own PS ratio has fluctuated wildly, from a high above 9 in early 2021 to the current level near 0.5; this places it near the very bottom of its multi-year historical range, suggesting the market is pricing in either a deep value opportunity or expectations of continued fundamental deterioration and margin pressure.
PE
-4.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -74x~61x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
55.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are dominated by extreme leverage, with a debt-to-equity ratio of 3.19 creating a significant interest burden and refinancing risk. Profitability is highly volatile, as evidenced by the swing from a $1.357 billion net loss in Q3 to a $19 million profit in Q4, raising sustainability concerns. While free cash flow of $803 million provides a near-term buffer, the company remains dependent on maintaining or improving its current 17.4% gross margin to service debt and fund operations, leaving it vulnerable to input cost inflation.
Market & Competitive Risks include valuation compression, as the stock trades at a PS ratio of 0.49, a deep discount to industry peers, which could persist if growth remains elusive. The stock's beta of 0.808 suggests it is less volatile than the market, but its severe 1-month underperformance (-17.85% vs. S&P 500) indicates acute sector-specific or company-specific headwinds, such as weak chemical industry demand. Competitive pressures and sensitivity to global industrial production cycles pose ongoing threats to revenue, which already declined 7% YoY in Q4.
Worst-Case Scenario involves a relapse into significant losses, similar to Q3 2025, triggered by a sharp downturn in key end-markets like automotive or electronics. This could lead to a credit rating downgrade, tightening liquidity, and forcing asset sales or equity dilution. The realistic downside is quantified by the 52-week low of $35.13, which represents a -38% decline from the current price of $56.80. A re-test of this level is plausible if the Q4 recovery proves fleeting and leverage concerns intensify, potentially leading to a max drawdown approaching its historical -43%.
FAQ
The key risks, in order of severity, are: 1) Financial Risk: An extremely high debt-to-equity ratio of 3.19 creates vulnerability to rising rates and economic downturns. 2) Operational Risk: Highly volatile profitability, with a trailing net margin of -12.2%, raises doubts about earnings sustainability. 3) Market Risk: Revenue declined 7% YoY in Q4, indicating weak underlying demand in its cyclical end-markets. 4) Sentiment Risk: The stock is under-followed (only 5 analysts) and has shown severe recent underperformance (-17.85% in 1 month vs. market), making it prone to sharp swings on news.
The 12-month forecast is highly uncertain, with three distinct scenarios. The base case (50% probability) sees the stock trading between $55 and $65, as volatility persists but the company avoids another major loss. The bull case (25% probability) targets $70 to $75 on a successful debt reduction and earnings beat. The bear case (25% probability) warns of a drop to $35-$45 if profitability collapses again. The most likely scenario is the base case, which assumes the company muddles through with stabilized but unspectacular results, as the high debt load prevents a swift re-rating. The key assumption is that free cash flow remains robust enough to service, but not rapidly pay down, its obligations.
CE appears significantly undervalued on a relative and historical basis, but this discount is justified by its risk profile. The trailing PS ratio of 0.49 is a deep discount to the chemical industry average. The forward P/E of 8.6x, based on an EPS estimate of $11.95, is also low. Historically, its own PS ratio has fallen from above 9 to the current 0.5 level. However, the market is assigning this low valuation due to the company's high financial leverage, negative trailing profitability, and revenue decline. The valuation implies the market expects minimal growth and significant ongoing risk, making it fairly valued to slightly undervalued when risks are fully priced in.
CE is a high-risk, high-potential-reward stock that may be a good buy only for specific investors. For risk-tolerant value investors seeking a deep discount (PS ratio of 0.49) and a turnaround story, the current price offers an entry point. The 25% probability bull case implies ~30% upside to the $70+ range. However, the severe bear case with a -38% downside to $35, driven by high leverage (D/E of 3.19) and earnings volatility, makes it a poor choice for conservative or income-focused investors. It is a good buy only under the condition that the investor has a long horizon, a high risk tolerance, and conviction in management's ability to sustain the Q4 profitability rebound.
CE is unsuitable for short-term trading due to its high volatility, low analyst coverage, and sensitivity to quarterly earnings surprises. Its beta of 0.808 suggests it is less volatile than the market, but its recent price action shows severe company-specific swings. The stock is more appropriate for a long-term (3-5 year) investment horizon, allowing time for a potential turnaround story to play out, debt to be gradually reduced, and the cyclical chemical industry to recover. The negligible dividend yield of 0.28% confirms this is not an income stock. A minimum holding period of 18-24 months is suggested to weather the inherent volatility and assess the sustainability of the operational recovery.